Current Recommendations for the Management of Bladder Cancer

Witjes, J. Alfred

doi:10.2165/00003495-199753030-00005

Cited by 24 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[17][18][19][20] While the chemotherapeutic potential of AD-32 was recognized earlier during preclinical studies, 17,18 its application has so far been limited to vesicular treatment of bladder cancer, primarily due to its poor water solubility. 21,34 Here, we report an attempt to overcome this solubility barrier by encapsulating the AD-32 in rHDL nanoparticles. [11][12][13][14][15][16] The advantageous characteristics of HDL-based drug carriers include small size, selective delivery via receptor targeting, stability during storage, and high payload capacity.…”

Section: Discussionmentioning

confidence: 99%

“…[13][14][15][16] The current study was undertaken to evaluate the in vitro therapeutic eff icacy of valrubicin [AD-32 (N-trifluoroacetyladriamycin-14-valerate)], a derivative of doxorubicin, which was originally developed as a cancer therapeutic agent, [17][18][19] leading to its restricted approval for treating Bacillus Calmette-Guerin (BCG)-resistant bladder cancers in 1998. 20,21 Even though AD-32 has been found to be much less toxic to normal tissues 16,22 than doxorubicin during preclinical studies, its therapeutic application has been confined to nonsystemic administration due to its poor water solubility. This restriction remains in place except for recent attempts to extend the application of AD-32 to treat skin cancer and psoriasis via topical formulations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Sabnis¹,

Nair²,

Israel³

et al. 2012

IJN

View full text Add to dashboard Cite

Among numerous drug-delivery approaches, reconstituted high-density lipoprotein (rHDL) nanocarriers have proven particularly applicable for delivering highly hydrophobic drugs. In this study, we have investigated the enhancement of the therapeutic impact of valrubicin (AD-32), an antineoplastic agent that has been limited to intravesicular application against bladder cancer, despite the encouraging original preclinical data. Earlier studies validated the superior therapeutic efficacy of AD-32 over doxorubicin. In the present study, rHDL/AD-32 nanoparticles were formulated and characterized with regard to encapsulation efficiency, physicochemical properties, selective toxicity, and receptor-mediated uptake. The half maximal inhibitory concentration values (IC 50 ) for rHDL/AD-32 nanoparticles were 1.8 and 2.6 times lower than the free AD-32 for prostate (PC-3) and ovarian (SKOV-3) cancer cell lines, respectively, whereas nonmalignant cell lines demonstrated 5 and 1.48 times higher IC 50 doses with rHDL/AD-32 formulations. The data obtained demonstrated effective receptor-mediated uptake of AD-32 from the rHDL nanocarriers by PC-3 and SKOV-3 cancer cells via a targeted drug-delivery process. The rHDL/AD-32 formulation was stable for 6 months when stored at 4°C or at -20°C, as 92% of the AD-32 was retained in the nanoparticles. The findings from this study show that the rHDL/AD-32 formulation can overcome the solubility barriers of AD-32 and thus serve as an effective systemically administered chemotherapeutic agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Sabnis¹,

Nair²,

Israel³

et al. 2012

IJN

View full text Add to dashboard Cite

show abstract

“…1,2) Brendler et al also reported intravesical instillation therapy with oxybutynin (OB) hydrochloride, 3) an anti-cholinergic, in neurogenetic bladder, and the clinical usefulness of the therapy has been demonstrated by other research groups. [4][5][6][7] Enhanced effectiveness resulting from direct action on the bladder smooth muscle, and reductions in general side effects are advantages of intravesical instillation of drug solution.…”

mentioning

confidence: 99%

Formulation Study of Intravesical Oxybutynin Instillation Solution with Enhanced Retention in Bladder

Hanawa

Tsuchiya

Endo

et al. 2008

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

A formulation study of intravesical oxybutynin (OB) preparations was carried out in order to improve the effectiveness in intravesical instillation therapy for spastic neurogenetic bladder. Sodium hyaluronate (HYA) was introduced to enhance the muco-adhesiveness of the instillation preparation, and the physicochemical properties of the OB formulation were evaluated in comparison with a conventional formulation containing hydroxypropylcellulose (HPC). The viscous properties and in vitro adhesiveness increased with the amount of the polymeric additives, and retention properties of OB in rabbit bladder were comparable after addition of 0.4% HYA and 1.0% HPC. HYA was able to enhance the intravesical retention properties of OB instillation solution to a lesser degree than HPC, it seemed to be a useful additive in the OB instillation due to its safety and mucosal-protective effect.

show abstract

“…These tumours demonstrate a higher tendency to recur either at the same stage and grade or as deeply invasive tumours after initial surgical resection (Hurle et al, 1996;Lamm and Torti, 1996;Esrig et al, 1997). This biological behaviour constitutes a common clinical dilemma as far as an optimal management and points to the need for an effective prophylactic treatment of these tumours (Carballido et al, 1990a;Kurth, 1997;Kurth et al, 1997;Molt-et al, 1997;Witjes, 1997) after their transurethral resection of the tumor (Patard et al, 1993;Molto et al, 1995).…”

mentioning

confidence: 99%

“…Intravesical instillation of several immunomodulators, such as bacillus CalmetteÐGuŽrin (BCG), has been proposed as prophylactic adjuvant therapy (Erton et al, 1996;Kurth, 1997b;Witjes, 1997). The mechanism of action of intracavitary instillations with BCG remains partially known.…”

mentioning

confidence: 99%

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

et al. 1999

View full text Add to dashboard Cite

SummaryWe investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guérin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA-DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).

show abstract

Current Recommendations for the Management of Bladder Cancer

Cited by 24 publications

References 51 publications

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Formulation Study of Intravesical Oxybutynin Instillation Solution with Enhanced Retention in Bladder

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

Contact Info

Product

Resources

About